Tislelizumab meets overall survival endpoint in later-line NSCLC at planned interim analysis, but faces exploding competition in the Chinese immuno-oncology sector.
BeiGene, Ltd.’s tislelizumab has met its overall survival primary endpoint in a Phase III trial for later-line use in non-small cell lung cancer (NSCLC), in what is the first positive global pivotal clinical trial result for the Chinese firm’s anti-PD-1 antibody.
The drug, already approved in China (as Baize'An) for lymphoma and urothelial cancer, is in a broad clinical program, including...
Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.
CEO Ben Zeskind said all options are on the table after atebimetinib showed impressive results in pancreatic cancer.
The company believes its drug could eventually displace Novartis’s Scemblix in first-line chronic myeloid leukemia treatment, but for now is preparing for a second-/third-line pivotal study.
The drugmaker presented data at a lymphoma meeting showing strong efficacy for the CAR-T in marginal zone lymphoma, the second most common indolent lymphoma.
The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.
Wales-based group launches with $140m series A.
CEO Ben Zeskind said all options are on the table after atebimetinib showed impressive results in pancreatic cancer.
